NCT02783300 (Meteor 1) is a Phase 1 clinical trial of GSK3326595 in Neoplasms, sponsored by GlaxoSmithKline.

Who is sponsoring NCT02783300?

NCT02783300 is sponsored by GlaxoSmithKline.

What drugs are being tested in NCT02783300?

Interventions in NCT02783300: GSK3326595, Pembrolizumab.

Is NCT02783300 still recruiting?

NCT02783300 is currently completed. Last updated 10 March 2025.

Are results published for NCT02783300?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-03-10 · How we verify

NCT02783300: Meteor 1

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma

Completed Phase 1 Results posted Last updated 10 March 2025

What this trial tests

Phase 1 trial testing GSK3326595 in Neoplasms in 297 participants. Completed in 30 August 2023.

Timeline

30 August 2016

Primary endpoint
30 August 2023

30 August 2023

Quick facts

Lead sponsor	GlaxoSmithKline
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	297
Start date	30 August 2016
Primary completion	30 August 2023
Estimated completion	30 August 2023
Sites	15 locations across France, Canada, United States, Netherlands

Drugs / interventions tested

GSK3326595 — full drug profile →
Pembrolizumab (pembrolizumab) — full drug profile →

Conditions studied

Neoplasms — all drugs for Neoplasms →

Sponsor

GlaxoSmithKline — full company profile →

Who can join

18 and older, any sex, with Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Part 1: Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs) Primary · Up to 30 months

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, or is a congenital anomaly/birth defect, other situations which involved medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are

Any AEs

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	1
Part 1: GSK3326595 25mg QD	1
Part 1: GSK3326595 50mg QD	1
Part 1: GSK3326595 100mg QD	1
Part 1: GSK3326595 200mg QD	7
Part 1: GSK3326595 300mg QD	3
Part 1: GSK3326595 400mg QD	19
Part 1: GSK3326595 600mg QD	3
Part 1: GSK3326595 50mg Twice Daily (BID)	1
Part 1: GSK3326595 100mg BID	7
Part 1: GSK3326595 150mg BID	6
Part 1: GSK3326595 200mg BID	3

Any SAEs

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	0
Part 1: GSK3326595 25mg QD	0
Part 1: GSK3326595 50mg QD	0
Part 1: GSK3326595 100mg QD	0
Part 1: GSK3326595 200mg QD	4
Part 1: GSK3326595 300mg QD	1
Part 1: GSK3326595 400mg QD	10
Part 1: GSK3326595 600mg QD	1
Part 1: GSK3326595 50mg Twice Daily (BID)	0
Part 1: GSK3326595 100mg BID	2
Part 1: GSK3326595 150mg BID	3
Part 1: GSK3326595 200mg BID	3

Part 1: Number of Participants Withdrawn Due to AEs Primary · Up to 30 months

The data for number of participants withdrawn due to AEs have been presented.

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	0
Part 1: GSK3326595 25mg QD	0
Part 1: GSK3326595 50mg QD	0
Part 1: GSK3326595 100mg QD	0
Part 1: GSK3326595 200mg QD	2
Part 1: GSK3326595 300mg QD	0
Part 1: GSK3326595 400mg QD	2
Part 1: GSK3326595 600mg QD	0
Part 1: GSK3326595 50mg Twice Daily (BID)	0
Part 1: GSK3326595 100mg BID	0
Part 1: GSK3326595 150mg BID	0
Part 1: GSK3326595 200mg BID	1

Part 1: Number of Participants With Dose Limiting Toxicities (DLTs) Primary · Up to 21 days

DLT is considered to be clinically relevant AE by investigator if it met at least one of the criteria: Grade(G)3 neutropenia for \>=5 days/G4 neutropenia of any duration, G3 or greater febrile neutropenia, G4 or greater anemia of any duration and thrombocytopenia, or G3 thrombocytopenia with bleeding, Alanine aminotransferase (ALT) \>3x upper limit of normal (ULN)+bilirubin, \>=2xULN or ALT between 3-5 X ULN with bilirubin \< 2Xuln but with hepatitis symptoms/rash, G3 nausea/vomiting/diarrhea that does not improve within 72 hour, G4 or greater nausea/vomiting/diarrhea, G3 or greater hypertensi

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	0
Part 1: GSK3326595 25mg QD	0
Part 1: GSK3326595 50mg QD	0
Part 1: GSK3326595 100mg QD	0
Part 1: GSK3326595 200mg QD	0
Part 1: GSK3326595 300mg QD	1
Part 1: GSK3326595 400mg QD	2
Part 1: GSK3326595 600mg QD	0
Part 1: GSK3326595 50mg Twice Daily (BID)	0
Part 1: GSK3326595 100mg BID	0
Part 1: GSK3326595 150mg BID	1
Part 1: GSK3326595 200mg BID	1

Part 1: Number of Participants With Dose Modifications of GSK3326595 Primary · Up to 30 months

The number of participants who experienced any dose modifications (interruptions and reductions) of GSK3326595 have been presented.

Dose interruptions

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	1
Part 1: GSK3326595 25mg QD	1
Part 1: GSK3326595 50mg QD	1
Part 1: GSK3326595 100mg QD	1
Part 1: GSK3326595 200mg QD	5
Part 1: GSK3326595 300mg QD	3
Part 1: GSK3326595 400mg QD	18
Part 1: GSK3326595 600mg QD	2
Part 1: GSK3326595 50mg Twice Daily (BID)	0
Part 1: GSK3326595 100mg BID	5
Part 1: GSK3326595 150mg BID	4
Part 1: GSK3326595 200mg BID	2

Dose reductions

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	0
Part 1: GSK3326595 25mg QD	0
Part 1: GSK3326595 50mg QD	0
Part 1: GSK3326595 100mg QD	0
Part 1: GSK3326595 200mg QD	0
Part 1: GSK3326595 300mg QD	1
Part 1: GSK3326595 400mg QD	16
Part 1: GSK3326595 600mg QD	2
Part 1: GSK3326595 50mg Twice Daily (BID)	0
Part 1: GSK3326595 100mg BID	2
Part 1: GSK3326595 150mg BID	2
Part 1: GSK3326595 200mg BID	3

Part 1: Number of Participants With Worst Case Change From Baseline in Clinical Chemistry Parameters Primary · Baseline (Day 1) and up to 30 months

Blood samples were collected for evaluation of clinical chemistry parameters. The summaries of worst-case change from Baseline with respect to normal range have been presented for only those laboratory tests that are gradable by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The number of participants with decreases to low, changes to normal or no changes from Baseline, and increases to high values have been presented. Participants were counted twice if the participants have values that changed 'To Low' and 'To High', so the percentages may not add to 100%.

Alanine Aminotransferase, decreases to low

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	0
Part 1: GSK3326595 25mg QD	0
Part 1: GSK3326595 50mg QD	0
Part 1: GSK3326595 100mg QD	0
Part 1: GSK3326595 200mg QD	2
Part 1: GSK3326595 300mg QD	0
Part 1: GSK3326595 400mg QD	4
Part 1: GSK3326595 600mg QD	1
Part 1: GSK3326595 50mg Twice Daily (BID)	0
Part 1: GSK3326595 100mg BID	0
Part 1: GSK3326595 150mg BID	1
Part 1: GSK3326595 200mg BID	1

Alanine Aminotransferase, changes to normal or no changes

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	0
Part 1: GSK3326595 25mg QD	1
Part 1: GSK3326595 50mg QD	1
Part 1: GSK3326595 100mg QD	1
Part 1: GSK3326595 200mg QD	4
Part 1: GSK3326595 300mg QD	1
Part 1: GSK3326595 400mg QD	13
Part 1: GSK3326595 600mg QD	1
Part 1: GSK3326595 50mg Twice Daily (BID)	1
Part 1: GSK3326595 100mg BID	6
Part 1: GSK3326595 150mg BID	4
Part 1: GSK3326595 200mg BID	2

Alanine Aminotransferase, increases to high

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	1
Part 1: GSK3326595 25mg QD	0
Part 1: GSK3326595 50mg QD	0
Part 1: GSK3326595 100mg QD	0
Part 1: GSK3326595 200mg QD	1
Part 1: GSK3326595 300mg QD	2
Part 1: GSK3326595 400mg QD	2
Part 1: GSK3326595 600mg QD	1
Part 1: GSK3326595 50mg Twice Daily (BID)	0
Part 1: GSK3326595 100mg BID	1
Part 1: GSK3326595 150mg BID	1
Part 1: GSK3326595 200mg BID	0

Albumin, decreases to low

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	1
Part 1: GSK3326595 25mg QD	1
Part 1: GSK3326595 50mg QD	1
Part 1: GSK3326595 100mg QD	1
Part 1: GSK3326595 200mg QD	4
Part 1: GSK3326595 300mg QD	1
Part 1: GSK3326595 400mg QD	12
Part 1: GSK3326595 600mg QD	1
Part 1: GSK3326595 50mg Twice Daily (BID)	0
Part 1: GSK3326595 100mg BID	2
Part 1: GSK3326595 150mg BID	5
Part 1: GSK3326595 200mg BID	1

Albumin, changes to normal or no changes

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	0
Part 1: GSK3326595 25mg QD	0
Part 1: GSK3326595 50mg QD	0
Part 1: GSK3326595 100mg QD	0
Part 1: GSK3326595 200mg QD	3
Part 1: GSK3326595 300mg QD	2
Part 1: GSK3326595 400mg QD	7
Part 1: GSK3326595 600mg QD	2
Part 1: GSK3326595 50mg Twice Daily (BID)	1
Part 1: GSK3326595 100mg BID	5
Part 1: GSK3326595 150mg BID	1
Part 1: GSK3326595 200mg BID	2

Albumin, increases to high

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	0
Part 1: GSK3326595 25mg QD	0
Part 1: GSK3326595 50mg QD	0
Part 1: GSK3326595 100mg QD	0
Part 1: GSK3326595 200mg QD	0
Part 1: GSK3326595 300mg QD	0
Part 1: GSK3326595 400mg QD	0
Part 1: GSK3326595 600mg QD	0
Part 1: GSK3326595 50mg Twice Daily (BID)	0
Part 1: GSK3326595 100mg BID	0
Part 1: GSK3326595 150mg BID	0
Part 1: GSK3326595 200mg BID	0

Alkaline Phosphatase, decreases to low

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	0
Part 1: GSK3326595 25mg QD	0
Part 1: GSK3326595 50mg QD	0
Part 1: GSK3326595 100mg QD	0
Part 1: GSK3326595 200mg QD	0
Part 1: GSK3326595 300mg QD	0
Part 1: GSK3326595 400mg QD	0
Part 1: GSK3326595 600mg QD	0
Part 1: GSK3326595 50mg Twice Daily (BID)	0
Part 1: GSK3326595 100mg BID	0
Part 1: GSK3326595 150mg BID	0
Part 1: GSK3326595 200mg BID	0

Alkaline Phosphatase, changes to normal or no changes

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	1
Part 1: GSK3326595 25mg QD	1
Part 1: GSK3326595 50mg QD	1
Part 1: GSK3326595 100mg QD	0
Part 1: GSK3326595 200mg QD	7
Part 1: GSK3326595 300mg QD	2
Part 1: GSK3326595 400mg QD	17
Part 1: GSK3326595 600mg QD	1
Part 1: GSK3326595 50mg Twice Daily (BID)	0
Part 1: GSK3326595 100mg BID	4
Part 1: GSK3326595 150mg BID	5
Part 1: GSK3326595 200mg BID	3

Part 1: Number of Participants With Worst Case Change From Baseline in Hematology Parameters Primary · Baseline (Day 1) and up to 30 months

Blood samples were collected for evaluation of hematology parameters. The summaries of worst-case change from Baseline with respect to normal range have been presented for only those laboratory tests that are gradable by CTCAE v5.0. The number of participants with decreases to low, changes to normal or no changes from Baseline, and increases to high values have been presented. Participants were counted twice if the participants have values that changed 'To Low' and 'To High', so the percentages may not add to 100%.

Basophils, decreases to low

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	0
Part 1: GSK3326595 25mg QD	0
Part 1: GSK3326595 50mg QD	0
Part 1: GSK3326595 100mg QD	0
Part 1: GSK3326595 200mg QD	0
Part 1: GSK3326595 300mg QD	0
Part 1: GSK3326595 400mg QD	0
Part 1: GSK3326595 600mg QD	0
Part 1: GSK3326595 50mg Twice Daily (BID)	0
Part 1: GSK3326595 100mg BID	0
Part 1: GSK3326595 150mg BID	0
Part 1: GSK3326595 200mg BID	0

Basophils, changes to normal or no changes

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	1
Part 1: GSK3326595 25mg QD	1
Part 1: GSK3326595 50mg QD	1
Part 1: GSK3326595 100mg QD	1
Part 1: GSK3326595 200mg QD	6
Part 1: GSK3326595 300mg QD	2
Part 1: GSK3326595 400mg QD	19
Part 1: GSK3326595 600mg QD	3
Part 1: GSK3326595 50mg Twice Daily (BID)	1
Part 1: GSK3326595 100mg BID	7
Part 1: GSK3326595 150mg BID	6
Part 1: GSK3326595 200mg BID	2

Basophils, increases to high

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	0
Part 1: GSK3326595 25mg QD	0
Part 1: GSK3326595 50mg QD	0
Part 1: GSK3326595 100mg QD	0
Part 1: GSK3326595 200mg QD	1
Part 1: GSK3326595 300mg QD	1
Part 1: GSK3326595 400mg QD	0
Part 1: GSK3326595 600mg QD	0
Part 1: GSK3326595 50mg Twice Daily (BID)	0
Part 1: GSK3326595 100mg BID	0
Part 1: GSK3326595 150mg BID	0
Part 1: GSK3326595 200mg BID	1

Eosinophils, decreases to low

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	0
Part 1: GSK3326595 25mg QD	1
Part 1: GSK3326595 50mg QD	0
Part 1: GSK3326595 100mg QD	0
Part 1: GSK3326595 200mg QD	2
Part 1: GSK3326595 300mg QD	0
Part 1: GSK3326595 400mg QD	1
Part 1: GSK3326595 600mg QD	0
Part 1: GSK3326595 50mg Twice Daily (BID)	0
Part 1: GSK3326595 100mg BID	0
Part 1: GSK3326595 150mg BID	0
Part 1: GSK3326595 200mg BID	0

Eosinophils, changes to normal or no changes

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	1
Part 1: GSK3326595 25mg QD	0
Part 1: GSK3326595 50mg QD	1
Part 1: GSK3326595 100mg QD	1
Part 1: GSK3326595 200mg QD	5
Part 1: GSK3326595 300mg QD	3
Part 1: GSK3326595 400mg QD	16
Part 1: GSK3326595 600mg QD	3
Part 1: GSK3326595 50mg Twice Daily (BID)	1
Part 1: GSK3326595 100mg BID	6
Part 1: GSK3326595 150mg BID	6
Part 1: GSK3326595 200mg BID	0

Eosinophils, increases to high

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	0
Part 1: GSK3326595 25mg QD	0
Part 1: GSK3326595 50mg QD	0
Part 1: GSK3326595 100mg QD	0
Part 1: GSK3326595 200mg QD	0
Part 1: GSK3326595 300mg QD	0
Part 1: GSK3326595 400mg QD	2
Part 1: GSK3326595 600mg QD	0
Part 1: GSK3326595 50mg Twice Daily (BID)	0
Part 1: GSK3326595 100mg BID	1
Part 1: GSK3326595 150mg BID	0
Part 1: GSK3326595 200mg BID	3

Mean Corpuscular Hemoglobin, decreases to low

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	0
Part 1: GSK3326595 25mg QD	0
Part 1: GSK3326595 50mg QD	0
Part 1: GSK3326595 100mg QD	0
Part 1: GSK3326595 200mg QD	2
Part 1: GSK3326595 300mg QD	0
Part 1: GSK3326595 400mg QD	1
Part 1: GSK3326595 600mg QD	0
Part 1: GSK3326595 50mg Twice Daily (BID)	0
Part 1: GSK3326595 100mg BID	2
Part 1: GSK3326595 150mg BID	0
Part 1: GSK3326595 200mg BID	1

Mean Corpuscular Hemoglobin, changes to normal or no changes

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	1
Part 1: GSK3326595 25mg QD	1
Part 1: GSK3326595 50mg QD	1
Part 1: GSK3326595 100mg QD	1
Part 1: GSK3326595 200mg QD	5
Part 1: GSK3326595 300mg QD	3
Part 1: GSK3326595 400mg QD	17
Part 1: GSK3326595 600mg QD	2
Part 1: GSK3326595 50mg Twice Daily (BID)	0
Part 1: GSK3326595 100mg BID	5
Part 1: GSK3326595 150mg BID	6
Part 1: GSK3326595 200mg BID	1

Part 1: Number of Participants With Worst Case Change From Baseline in Coagulation Parameters Primary · Baseline (Day 1) and up to 30 months

Blood samples were collected for evaluation of coagulation parameters. The summaries of worst-case change from Baseline with respect to normal range have been presented for only those laboratory tests that are gradable by CTCAE v4.0. The number of participants with decreases to low, changes to normal or no changes from Baseline, and increases to high values have been presented. Participants were counted twice if the participants have values that changed 'To Low' and 'To High', so the percentages may not add to 100%.

Partial Thromboplastin Time, decreases to low

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	0
Part 1: GSK3326595 25mg QD	0
Part 1: GSK3326595 50mg QD	0
Part 1: GSK3326595 100mg QD	0
Part 1: GSK3326595 200mg QD	0
Part 1: GSK3326595 300mg QD	0
Part 1: GSK3326595 400mg QD	1
Part 1: GSK3326595 600mg QD	0
Part 1: GSK3326595 50mg Twice Daily (BID)	1
Part 1: GSK3326595 100mg BID	0
Part 1: GSK3326595 150mg BID	0
Part 1: GSK3326595 200mg BID	0

Partial Thromboplastin Time, changes to normal or no changes

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	1
Part 1: GSK3326595 25mg QD	0
Part 1: GSK3326595 50mg QD	1
Part 1: GSK3326595 100mg QD	0
Part 1: GSK3326595 200mg QD	4
Part 1: GSK3326595 300mg QD	1
Part 1: GSK3326595 400mg QD	8
Part 1: GSK3326595 600mg QD	1
Part 1: GSK3326595 50mg Twice Daily (BID)	0
Part 1: GSK3326595 100mg BID	4
Part 1: GSK3326595 150mg BID	1
Part 1: GSK3326595 200mg BID	1

Partial Thromboplastin Time, increases to high

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	0
Part 1: GSK3326595 25mg QD	1
Part 1: GSK3326595 50mg QD	0
Part 1: GSK3326595 100mg QD	1
Part 1: GSK3326595 200mg QD	3
Part 1: GSK3326595 300mg QD	1
Part 1: GSK3326595 400mg QD	6
Part 1: GSK3326595 600mg QD	2
Part 1: GSK3326595 50mg Twice Daily (BID)	0
Part 1: GSK3326595 100mg BID	1
Part 1: GSK3326595 150mg BID	3
Part 1: GSK3326595 200mg BID	1

Prothrombin Intl. Normalized Ratio, decreases to low

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	0
Part 1: GSK3326595 25mg QD	0
Part 1: GSK3326595 50mg QD	0
Part 1: GSK3326595 100mg QD	0
Part 1: GSK3326595 200mg QD	0
Part 1: GSK3326595 300mg QD	0
Part 1: GSK3326595 400mg QD	1
Part 1: GSK3326595 600mg QD	0
Part 1: GSK3326595 50mg Twice Daily (BID)	0
Part 1: GSK3326595 100mg BID	0
Part 1: GSK3326595 150mg BID	0
Part 1: GSK3326595 200mg BID	0

Prothrombin Intl. Normalized Ratio, changes to normal or no changes

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	1
Part 1: GSK3326595 25mg QD	1
Part 1: GSK3326595 50mg QD	0
Part 1: GSK3326595 100mg QD	0
Part 1: GSK3326595 200mg QD	4
Part 1: GSK3326595 300mg QD	2
Part 1: GSK3326595 400mg QD	8
Part 1: GSK3326595 600mg QD	1
Part 1: GSK3326595 50mg Twice Daily (BID)	0
Part 1: GSK3326595 100mg BID	2
Part 1: GSK3326595 150mg BID	2
Part 1: GSK3326595 200mg BID	2

Prothrombin Intl. Normalized Ratio, increases to high

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	0
Part 1: GSK3326595 25mg QD	0
Part 1: GSK3326595 50mg QD	1
Part 1: GSK3326595 100mg QD	1
Part 1: GSK3326595 200mg QD	3
Part 1: GSK3326595 300mg QD	1
Part 1: GSK3326595 400mg QD	10
Part 1: GSK3326595 600mg QD	2
Part 1: GSK3326595 50mg Twice Daily (BID)	1
Part 1: GSK3326595 100mg BID	5
Part 1: GSK3326595 150mg BID	4
Part 1: GSK3326595 200mg BID	1

Prothrombin Time, decreases to low

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	0
Part 1: GSK3326595 25mg QD	0
Part 1: GSK3326595 50mg QD	0
Part 1: GSK3326595 100mg QD	0
Part 1: GSK3326595 200mg QD	0
Part 1: GSK3326595 300mg QD	0
Part 1: GSK3326595 400mg QD	1
Part 1: GSK3326595 600mg QD	0
Part 1: GSK3326595 50mg Twice Daily (BID)	0
Part 1: GSK3326595 100mg BID	0
Part 1: GSK3326595 150mg BID	0
Part 1: GSK3326595 200mg BID	0

Prothrombin Time, changes to normal or no changes

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	1
Part 1: GSK3326595 25mg QD	1
Part 1: GSK3326595 50mg QD	0
Part 1: GSK3326595 100mg QD	1
Part 1: GSK3326595 200mg QD	3
Part 1: GSK3326595 300mg QD	3
Part 1: GSK3326595 400mg QD	9
Part 1: GSK3326595 600mg QD	1
Part 1: GSK3326595 50mg Twice Daily (BID)	0
Part 1: GSK3326595 100mg BID	4
Part 1: GSK3326595 150mg BID	3
Part 1: GSK3326595 200mg BID	3

Part 1: Number of Participants With Worst Case Change From Baseline in Urinalysis Parameters Primary · Baseline (Day 1) and up to 30 months

Urine samples were collected for evaluation of urinalysis parameters. The summaries of worst-case change from Baseline with respect to normal range have been presented for only those laboratory tests that are gradable by CTCAE v5.0. The number of participants with no change or change to negative and change to positive have been presented.

Occult Blood, No Change or Change to Negative

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	0
Part 1: GSK3326595 25mg QD	1
Part 1: GSK3326595 50mg QD	0
Part 1: GSK3326595 100mg QD	1
Part 1: GSK3326595 200mg QD	5
Part 1: GSK3326595 300mg QD	2
Part 1: GSK3326595 400mg QD	12
Part 1: GSK3326595 600mg QD	2
Part 1: GSK3326595 50mg Twice Daily (BID)	1
Part 1: GSK3326595 100mg BID	4
Part 1: GSK3326595 150mg BID	4
Part 1: GSK3326595 200mg BID	1

Occult Blood, Change to Positive

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	1
Part 1: GSK3326595 25mg QD	0
Part 1: GSK3326595 50mg QD	1
Part 1: GSK3326595 100mg QD	0
Part 1: GSK3326595 200mg QD	2
Part 1: GSK3326595 300mg QD	1
Part 1: GSK3326595 400mg QD	7
Part 1: GSK3326595 600mg QD	1
Part 1: GSK3326595 50mg Twice Daily (BID)	0
Part 1: GSK3326595 100mg BID	3
Part 1: GSK3326595 150mg BID	2
Part 1: GSK3326595 200mg BID	2

Protein, No Change or Change to Negative

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	1
Part 1: GSK3326595 25mg QD	1
Part 1: GSK3326595 50mg QD	1
Part 1: GSK3326595 100mg QD	1
Part 1: GSK3326595 200mg QD	4
Part 1: GSK3326595 300mg QD	2
Part 1: GSK3326595 400mg QD	11
Part 1: GSK3326595 600mg QD	1
Part 1: GSK3326595 50mg Twice Daily (BID)	1
Part 1: GSK3326595 100mg BID	2
Part 1: GSK3326595 150mg BID	4
Part 1: GSK3326595 200mg BID	1

Protein, Change to Positive

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	0
Part 1: GSK3326595 25mg QD	0
Part 1: GSK3326595 50mg QD	0
Part 1: GSK3326595 100mg QD	0
Part 1: GSK3326595 200mg QD	3
Part 1: GSK3326595 300mg QD	1
Part 1: GSK3326595 400mg QD	8
Part 1: GSK3326595 600mg QD	2
Part 1: GSK3326595 50mg Twice Daily (BID)	0
Part 1: GSK3326595 100mg BID	5
Part 1: GSK3326595 150mg BID	2
Part 1: GSK3326595 200mg BID	2

Ketones, No Change or Change to Negative

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	1
Part 1: GSK3326595 25mg QD	1
Part 1: GSK3326595 50mg QD	1
Part 1: GSK3326595 100mg QD	1
Part 1: GSK3326595 200mg QD	5
Part 1: GSK3326595 300mg QD	2
Part 1: GSK3326595 400mg QD	11
Part 1: GSK3326595 600mg QD	2
Part 1: GSK3326595 50mg Twice Daily (BID)	0
Part 1: GSK3326595 100mg BID	3
Part 1: GSK3326595 150mg BID	3
Part 1: GSK3326595 200mg BID	3

Ketones, Change to Positive

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	0
Part 1: GSK3326595 25mg QD	0
Part 1: GSK3326595 50mg QD	0
Part 1: GSK3326595 100mg QD	0
Part 1: GSK3326595 200mg QD	2
Part 1: GSK3326595 300mg QD	1
Part 1: GSK3326595 400mg QD	8
Part 1: GSK3326595 600mg QD	1
Part 1: GSK3326595 50mg Twice Daily (BID)	1
Part 1: GSK3326595 100mg BID	4
Part 1: GSK3326595 150mg BID	3
Part 1: GSK3326595 200mg BID	0

Glucose, No Change or Change to Negative

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	1
Part 1: GSK3326595 25mg QD	1
Part 1: GSK3326595 50mg QD	1
Part 1: GSK3326595 100mg QD	1
Part 1: GSK3326595 200mg QD	7
Part 1: GSK3326595 300mg QD	3
Part 1: GSK3326595 400mg QD	18
Part 1: GSK3326595 600mg QD	3
Part 1: GSK3326595 50mg Twice Daily (BID)	1
Part 1: GSK3326595 100mg BID	7
Part 1: GSK3326595 150mg BID	5
Part 1: GSK3326595 200mg BID	3

Glucose, Change to Positive

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	0
Part 1: GSK3326595 25mg QD	0
Part 1: GSK3326595 50mg QD	0
Part 1: GSK3326595 100mg QD	0
Part 1: GSK3326595 200mg QD	0
Part 1: GSK3326595 300mg QD	0
Part 1: GSK3326595 400mg QD	1
Part 1: GSK3326595 600mg QD	0
Part 1: GSK3326595 50mg Twice Daily (BID)	0
Part 1: GSK3326595 100mg BID	0
Part 1: GSK3326595 150mg BID	1
Part 1: GSK3326595 200mg BID	0

Part 1: Changes From Baseline in Urine Potential of Hydrogen (pH) Primary · Baseline (Day 1) and up to week 132

Urine samples were collected from participants to assess urine pH levels.

Baseline

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	5.00	± NA
Part 1: GSK3326595 25mg QD	5.50	± NA
Part 1: GSK3326595 50mg QD	7.00	± NA
Part 1: GSK3326595 100mg QD	6.50	± NA
Part 1: GSK3326595 200mg QD	6.00	± 0.886
Part 1: GSK3326595 300mg QD	6.17	± 0.289
Part 1: GSK3326595 400mg QD	6.11	± 0.698
Part 1: GSK3326595 600mg QD	5.67	± 0.764
Part 1: GSK3326595 50mg Twice Daily (BID)	6.50	± NA
Part 1: GSK3326595 100mg BID	5.79	± 1.075
Part 1: GSK3326595 150mg BID	5.75	± 0.524
Part 1: GSK3326595 200mg BID	6.17	± 0.764

CFB to Day 8

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	0.00	± NA
Part 1: GSK3326595 25mg QD	0.00	± NA
Part 1: GSK3326595 50mg QD	-1.00	± NA
Part 1: GSK3326595 100mg QD	0.50	± NA
Part 1: GSK3326595 200mg QD	0.17	± 0.516
Part 1: GSK3326595 300mg QD	-0.25	± 0.354
Part 1: GSK3326595 400mg QD	-0.28	± 0.548
Part 1: GSK3326595 600mg QD	0.83	± 0.764
Part 1: GSK3326595 50mg Twice Daily (BID)	0.50	± NA
Part 1: GSK3326595 100mg BID	-0.07	± 1.239
Part 1: GSK3326595 150mg BID	0.08	± 0.492
Part 1: GSK3326595 200mg BID	0.33	± 1.258

CFB to Day 15

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	0.00	± NA
Part 1: GSK3326595 25mg QD	0.00	± NA
Part 1: GSK3326595 50mg QD	-1.00	± NA
Part 1: GSK3326595 100mg QD	0.50	± NA
Part 1: GSK3326595 200mg QD	0.21	± 0.488
Part 1: GSK3326595 300mg QD	-0.17	± 0.289
Part 1: GSK3326595 400mg QD	-0.24	± 0.731
Part 1: GSK3326595 600mg QD	0.00	± 1.000
Part 1: GSK3326595 50mg Twice Daily (BID)	0.00	± NA
Part 1: GSK3326595 100mg BID	-0.29	± 0.859
Part 1: GSK3326595 150mg BID	0.10	± 0.548
Part 1: GSK3326595 200mg BID	1.00	± NA

CFB to Week 4 Day 1

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	0.00	± NA
Part 1: GSK3326595 25mg QD	0.00	± NA
Part 1: GSK3326595 50mg QD	0.00	± NA
Part 1: GSK3326595 100mg QD	0.50	± NA
Part 1: GSK3326595 200mg QD	-0.20	± 0.447
Part 1: GSK3326595 300mg QD	-0.75	± 0.354
Part 1: GSK3326595 400mg QD	-0.13	± 0.611
Part 1: GSK3326595 600mg QD	0.67	± 1.041
Part 1: GSK3326595 50mg Twice Daily (BID)	-0.50	± NA
Part 1: GSK3326595 100mg BID	-0.21	± 0.488
Part 1: GSK3326595 150mg BID	0.10	± 0.548
Part 1: GSK3326595 300mg QD (Food Effect)	-0.10	± 0.849

CFB to Week 6 Day 1

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	0.00	± NA
Part 1: GSK3326595 25mg QD	0.00	± NA
Part 1: GSK3326595 50mg QD	0.00	± NA
Part 1: GSK3326595 100mg QD	0.50	± NA
Part 1: GSK3326595 200mg QD	-0.17	± 0.577
Part 1: GSK3326595 300mg QD	0.00	± 0.000
Part 1: GSK3326595 400mg QD	-0.43	± 0.799
Part 1: GSK3326595 600mg QD	0.25	± 1.061
Part 1: GSK3326595 50mg Twice Daily (BID)	-0.50	± NA
Part 1: GSK3326595 100mg BID	-0.29	± 1.035
Part 1: GSK3326595 150mg BID	-0.08	± 0.492
Part 1: GSK3326595 200mg BID	0.00	± 0.707

CFB to Week 8

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	0.00	± NA
Part 1: GSK3326595 25mg QD	-0.50	± NA
Part 1: GSK3326595 100mg QD	0.50	± NA
Part 1: GSK3326595 200mg QD	-1.17	± 1.155
Part 1: GSK3326595 300mg QD	-0.75	± 0.354
Part 1: GSK3326595 400mg QD	-0.19	± 0.630
Part 1: GSK3326595 600mg QD	1.00	± 0.707
Part 1: GSK3326595 100mg BID	0.75	± 0.645
Part 1: GSK3326595 150mg BID	-0.20	± 0.274
Part 1: GSK3326595 200mg BID	0.00	± 0.000
Part 1: GSK3326595 300mg QD (Food Effect)	0.44	± 0.682

CFB to Week 12

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	0.00	± NA
Part 1: GSK3326595 200mg QD	0.00	± 0.500
Part 1: GSK3326595 300mg QD	-0.50	± NA
Part 1: GSK3326595 400mg QD	-0.11	± 0.546
Part 1: GSK3326595 600mg QD	1.00	± 1.414
Part 1: GSK3326595 100mg BID	0.38	± 0.629
Part 1: GSK3326595 150mg BID	0.00	± NA
Part 1: GSK3326595 200mg BID	-0.25	± 1.061
Part 1: GSK3326595 300mg QD (Food Effect)	0.08	± 1.021

CFB to Week 16

Group	Value	95% CI
Part 1: GSK3326595 200mg QD	-0.25	± 1.061
Part 1: GSK3326595 300mg QD	0.00	± NA
Part 1: GSK3326595 400mg QD	0.14	± 0.690
Part 1: GSK3326595 600mg QD	0.50	± 1.414
Part 1: GSK3326595 100mg BID	0.33	± 0.289
Part 1: GSK3326595 150mg BID	0.00	± NA
Part 1: GSK3326595 200mg BID	0.00	± 0.000
Part 1: GSK3326595 300mg QD (Food Effect)	-0.13	± 0.250

Part 1: Changes From Baseline in Urine Specific Gravity Primary · Baseline (Day 1) and up to week 132

Urine samples were collected from participants to assess urine specific gravity.

Baseline

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	1.02	± NA
Part 1: GSK3326595 25mg QD	1.03	± NA
Part 1: GSK3326595 50mg QD	1.01	± NA
Part 1: GSK3326595 100mg QD	1.02	± NA
Part 1: GSK3326595 200mg QD	1.02	± 0.008
Part 1: GSK3326595 300mg QD	1.02	± 0.006
Part 1: GSK3326595 400mg QD	1.02	± 0.007
Part 1: GSK3326595 600mg QD	1.02	± 0.004
Part 1: GSK3326595 50mg Twice Daily (BID)	1.01	± NA
Part 1: GSK3326595 100mg BID	1.02	± 0.006
Part 1: GSK3326595 150mg BID	1.03	± 0.008
Part 1: GSK3326595 200mg BID	1.02	± 0.008

CFB to Day 8

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	-0.01	± NA
Part 1: GSK3326595 25mg QD	0.00	± NA
Part 1: GSK3326595 50mg QD	0.01	± NA
Part 1: GSK3326595 100mg QD	0.01	± NA
Part 1: GSK3326595 200mg QD	0.00	± 0.010
Part 1: GSK3326595 300mg QD	0.00	± 0.004
Part 1: GSK3326595 400mg QD	0.00	± 0.007
Part 1: GSK3326595 600mg QD	0.00	± 0.010
Part 1: GSK3326595 50mg Twice Daily (BID)	0.00	± NA
Part 1: GSK3326595 100mg BID	0.00	± 0.008
Part 1: GSK3326595 150mg BID	0.00	± 0.006
Part 1: GSK3326595 200mg BID	0.00	± 0.009

CFB to Day 15

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	-0.01	± NA
Part 1: GSK3326595 25mg QD	-0.01	± NA
Part 1: GSK3326595 50mg QD	0.01	± NA
Part 1: GSK3326595 100mg QD	0.00	± NA
Part 1: GSK3326595 200mg QD	0.00	± 0.010
Part 1: GSK3326595 300mg QD	-0.01	± 0.005
Part 1: GSK3326595 400mg QD	0.00	± 0.007
Part 1: GSK3326595 600mg QD	0.00	± 0.005
Part 1: GSK3326595 50mg Twice Daily (BID)	0.01	± NA
Part 1: GSK3326595 100mg BID	0.00	± 0.010
Part 1: GSK3326595 150mg BID	0.00	± 0.004
Part 1: GSK3326595 200mg BID	0.00

CFB to Week 4 Day 1

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	-0.01	± NA
Part 1: GSK3326595 25mg QD	-0.01	± NA
Part 1: GSK3326595 50mg QD	0.00	± NA
Part 1: GSK3326595 100mg QD	0.00	± NA
Part 1: GSK3326595 200mg QD	0.00	± 0.007
Part 1: GSK3326595 300mg QD	0.00	± 0.004
Part 1: GSK3326595 400mg QD	0.00	± 0.008
Part 1: GSK3326595 600mg QD	0.00	± 0.002
Part 1: GSK3326595 50mg Twice Daily (BID)	0.01	± NA
Part 1: GSK3326595 100mg BID	0.00	± 0.007
Part 1: GSK3326595 150mg BID	0.00	± 0.007
Part 1: GSK3326595 300mg QD (Food Effect)	0.00	± 0.007

CFB to Week 6 Day 1

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	-0.01	± NA
Part 1: GSK3326595 25mg QD	-0.01	± NA
Part 1: GSK3326595 50mg QD	0.01	± NA
Part 1: GSK3326595 100mg QD	0.01	± NA
Part 1: GSK3326595 200mg QD	0.00	± 0.008
Part 1: GSK3326595 300mg QD	-0.01	± 0.004
Part 1: GSK3326595 400mg QD	0.00	± 0.010
Part 1: GSK3326595 600mg QD	0.00	± 0.006
Part 1: GSK3326595 50mg Twice Daily (BID)	0.01	± NA
Part 1: GSK3326595 100mg BID	0.00	± 0.012
Part 1: GSK3326595 150mg BID	0.00	± 0.004
Part 1: GSK3326595 200mg BID	-0.01	± 0.007

CFB to Week 8

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	-0.01	± NA
Part 1: GSK3326595 25mg QD	0.00	± NA
Part 1: GSK3326595 100mg QD	0.01	± NA
Part 1: GSK3326595 200mg QD	0.00	± 0.008
Part 1: GSK3326595 300mg QD	-0.01	± 0.004
Part 1: GSK3326595 400mg QD	0.00	± 0.008
Part 1: GSK3326595 600mg QD	0.00	± 0.006
Part 1: GSK3326595 100mg BID	0.00	± 0.006
Part 1: GSK3326595 150mg BID	0.00	± 0.004
Part 1: GSK3326595 200mg BID	-0.01	± 0.007
Part 1: GSK3326595 300mg QD (Food Effect)	0.00	± 0.007

CFB to Week 12

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	-0.01	± NA
Part 1: GSK3326595 200mg QD	0.00	± 0.005
Part 1: GSK3326595 300mg QD	-0.01
Part 1: GSK3326595 400mg QD	0.00	± 0.008
Part 1: GSK3326595 600mg QD	-0.01	± 0.008
Part 1: GSK3326595 100mg BID	0.00	± 0.010
Part 1: GSK3326595 150mg BID	-0.01	± NA
Part 1: GSK3326595 200mg BID	-0.01	± 0.004
Part 1: GSK3326595 300mg QD (Food Effect)	0.00	± 0.006

CFB to Week 16

Group	Value	95% CI
Part 1: GSK3326595 200mg QD	0.00	± 0.011
Part 1: GSK3326595 300mg QD	-0.02	± NA
Part 1: GSK3326595 400mg QD	0.00	± 0.006
Part 1: GSK3326595 600mg QD	-0.01	± 0.004
Part 1: GSK3326595 100mg BID	-0.01	± 0.008
Part 1: GSK3326595 150mg BID	0.00	± NA
Part 1: GSK3326595 200mg BID	0.00	± 0.004
Part 1: GSK3326595 300mg QD (Food Effect)	0.00	± 0.004

Part 1: Number of Participants With Maximum Grade Worst Case Increase Post-baseline Relative to Baseline in Vital Signs Primary · Baseline (Day 1) and up to 30 months

The abnormal vital sign ranges are: Heart Rate:- Low (\<60 beats per minute (bpm)), Normal (\>=60 bpm to \<=100 bpm), High (\>100 bpm); Temperature:- Low (\<=35 degree Celsius (°C)), Normal (\>35 °C and \<38 °C), High (\>=38 °C); Systolic Blood Pressure:- Low (\<90 millimeter of mercury (mmHg)), Normal (\>=90 mmHg to \<120 mmHg), High (\>=120 mmHg); Diastolic Blood Pressure:- Low (\<60 mmHg), Normal (\>=60 mmHg to \<80 mmHg), High (\>=80 mmHg). Participants were counted in the worst-case category and their value changes to (low, normal or high), unless there is no change in their category. Par

Heart Rate, changes to low

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	0
Part 1: GSK3326595 25mg QD	0
Part 1: GSK3326595 50mg QD	0
Part 1: GSK3326595 100mg QD	0
Part 1: GSK3326595 200mg QD	1
Part 1: GSK3326595 300mg QD	0
Part 1: GSK3326595 400mg QD	2
Part 1: GSK3326595 600mg QD	0
Part 1: GSK3326595 50mg Twice Daily (BID)	0
Part 1: GSK3326595 100mg BID	1
Part 1: GSK3326595 150mg BID	0
Part 1: GSK3326595 200mg BID	0

Heart Rate, changes to normal or no changes

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	1
Part 1: GSK3326595 25mg QD	1
Part 1: GSK3326595 50mg QD	1
Part 1: GSK3326595 100mg QD	0
Part 1: GSK3326595 200mg QD	5
Part 1: GSK3326595 300mg QD	3
Part 1: GSK3326595 400mg QD	12
Part 1: GSK3326595 600mg QD	3
Part 1: GSK3326595 50mg Twice Daily (BID)	1
Part 1: GSK3326595 100mg BID	3
Part 1: GSK3326595 150mg BID	6
Part 1: GSK3326595 200mg BID	2

Heart Rate, changes to high

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	0
Part 1: GSK3326595 25mg QD	0
Part 1: GSK3326595 50mg QD	0
Part 1: GSK3326595 100mg QD	1
Part 1: GSK3326595 200mg QD	1
Part 1: GSK3326595 300mg QD	0
Part 1: GSK3326595 400mg QD	6
Part 1: GSK3326595 600mg QD	0
Part 1: GSK3326595 50mg Twice Daily (BID)	0
Part 1: GSK3326595 100mg BID	3
Part 1: GSK3326595 150mg BID	0
Part 1: GSK3326595 200mg BID	1

Temperature, changes to low

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	0
Part 1: GSK3326595 25mg QD	0
Part 1: GSK3326595 50mg QD	0
Part 1: GSK3326595 100mg QD	0
Part 1: GSK3326595 200mg QD	0
Part 1: GSK3326595 300mg QD	0
Part 1: GSK3326595 400mg QD	0
Part 1: GSK3326595 600mg QD	0
Part 1: GSK3326595 50mg Twice Daily (BID)	0
Part 1: GSK3326595 100mg BID	0
Part 1: GSK3326595 150mg BID	0
Part 1: GSK3326595 200mg BID	0

Temperature, changes to normal or no changes

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	1
Part 1: GSK3326595 25mg QD	1
Part 1: GSK3326595 50mg QD	1
Part 1: GSK3326595 100mg QD	1
Part 1: GSK3326595 200mg QD	6
Part 1: GSK3326595 300mg QD	3
Part 1: GSK3326595 400mg QD	17
Part 1: GSK3326595 600mg QD	3
Part 1: GSK3326595 50mg Twice Daily (BID)	1
Part 1: GSK3326595 100mg BID	6
Part 1: GSK3326595 150mg BID	6
Part 1: GSK3326595 200mg BID	3

Temperature, changes to high

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	0
Part 1: GSK3326595 25mg QD	0
Part 1: GSK3326595 50mg QD	0
Part 1: GSK3326595 100mg QD	0
Part 1: GSK3326595 200mg QD	1
Part 1: GSK3326595 300mg QD	0
Part 1: GSK3326595 400mg QD	2
Part 1: GSK3326595 600mg QD	0
Part 1: GSK3326595 50mg Twice Daily (BID)	0
Part 1: GSK3326595 100mg BID	1
Part 1: GSK3326595 150mg BID	0
Part 1: GSK3326595 200mg BID	0

Systolic Blood Pressure, changes to low

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	0
Part 1: GSK3326595 25mg QD	0
Part 1: GSK3326595 50mg QD	0
Part 1: GSK3326595 100mg QD	0
Part 1: GSK3326595 200mg QD	0
Part 1: GSK3326595 300mg QD	0
Part 1: GSK3326595 400mg QD	3
Part 1: GSK3326595 600mg QD	1
Part 1: GSK3326595 50mg Twice Daily (BID)	0
Part 1: GSK3326595 100mg BID	1
Part 1: GSK3326595 150mg BID	0
Part 1: GSK3326595 200mg BID	0

Systolic Blood Pressure, changes to normal or no changes

Group	Value	95% CI
Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)	0
Part 1: GSK3326595 25mg QD	1
Part 1: GSK3326595 50mg QD	1
Part 1: GSK3326595 100mg QD	1
Part 1: GSK3326595 200mg QD	5
Part 1: GSK3326595 300mg QD	2
Part 1: GSK3326595 400mg QD	9
Part 1: GSK3326595 600mg QD	1
Part 1: GSK3326595 50mg Twice Daily (BID)	1
Part 1: GSK3326595 100mg BID	5
Part 1: GSK3326595 150mg BID	5
Part 1: GSK3326595 200mg BID	1

Part 3: Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs) Primary · Up to 10 months

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, or was a congenital anomaly/birth defect, other situations which involve medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are

Any AEs

Group	Value	95% CI
Part 3: GSK3326595 100mg + Pembrolizumab 200mg	9

Any SAEs

Group	Value	95% CI
Part 3: GSK3326595 100mg + Pembrolizumab 200mg	5

Adverse events — posted to ClinicalTrials.gov

Time frame: All-cause mortality, non-serious adverse events (non-SAEs) and serious adverse events (SAEs) were collected up to 30 months for part 1, 42 months for part 2 and 10 months for part 3.. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Part 1: GSK3326595 12.5 Milligram (mg) Once a Day (QD)

Serious: 0/1 (0%)

Deaths: 1/1

Part 1: GSK3326595 25mg QD

Serious: 0/1 (0%)

Deaths: 1/1

Part 1: GSK3326595 50mg QD

Serious: 0/1 (0%)

Deaths: 1/1

Part 1: GSK3326595 100mg QD

Serious: 0/1 (0%)

Deaths: 0/1

Part 1: GSK3326595 200mg QD

Serious: 4/8 (50%)

Deaths: 7/8

Part 1: GSK3326595 300mg QD

Serious: 1/3 (33%)

Deaths: 3/3

Part 1: GSK3326595 400mg QD

Serious: 10/19 (53%)

Deaths: 13/19

Part 1: GSK3326595 600mg QD

Serious: 1/3 (33%)

Deaths: 3/3

Part 1: GSK3326595 50mg Twice Daily (BID)

Serious: 0/1 (0%)

Deaths: 1/1

Part 1: GSK3326595 100mg BID

Serious: 2/7 (29%)

Deaths: 6/7

Part 1: GSK3326595 150mg BID

Serious: 3/6 (50%)

Deaths: 6/6

Part 1: GSK3326595 200mg BID

Serious: 3/3 (100%)

Deaths: 3/3

Part 1: GSK3326595 300mg QD (Food Effect)

Serious: 6/15 (40%)

Deaths: 8/15

Part 2: GSK3326595 400mg (TNBC)

Serious: 13/22 (59%)

Deaths: 16/22

Part 2: GSK3326595 400mg (mTCC)

Serious: 7/16 (44%)

Deaths: 10/16

Part 2: GSK3326595 400mg (GBM)

Serious: 15/29 (52%)

Deaths: 22/29

Part 2: GSK3326595 400mg (ER+BC)

Serious: 10/37 (27%)

Deaths: 31/37

Part 2: GSK3326595 400mg (HPV+)

Serious: 13/28 (46%)

Deaths: 25/28

Part 2: GSK3326595 400mg (ACC)

Serious: 15/34 (44%)

Deaths: 20/34

Part 2: GSK3326595 300mg (ACC)

Serious: 5/16 (31%)

Deaths: 2/16

Part 2: GSK3326595 400mg (NHL P53 Mutant)

Serious: 4/6 (67%)

Deaths: 4/6

Part 2: GSK3326595 300mg (NHL P53 Mutant)

Serious: 2/2 (100%)

Deaths: 1/2

Part 2: GSK3326595 400mg (NHL P53 Wild Type)

Serious: 4/8 (50%)

Deaths: 5/8

Part 2: GSK3326595 300mg (NHL P53 Wild Type)

Serious: 0/2 (0%)

Deaths: 1/2

Part 2: GSK3326595 400mg (NHL P53 Unknown)

Serious: 4/11 (36%)

Deaths: 7/11

Part 2: GSK3326595 300mg (NSCLC)

Serious: 0/7 (0%)

Deaths: 3/7

Part 3: GSK3326595 100mg + Pembrolizumab 200mg

Serious: 5/10 (50%)

Deaths: 6/10

Serious adverse events (114 terms)

Reaction	System	Part 1: GSK3326595 12.5 Mi…	Part 1: GSK3326595 25mg QD	Part 1: GSK3326595 50mg QD	Part 1: GSK3326595 100mg QD	Part 1: GSK3326595 200mg QD	Part 1: GSK3326595 300mg QD	Part 1: GSK3326595 400mg QD	Part 1: GSK3326595 600mg QD	Part 1: GSK3326595 50mg Tw…	Part 1: GSK3326595 100mg BID	Part 1: GSK3326595 150mg BID	Part 1: GSK3326595 200mg BID	Part 1: GSK3326595 300mg Q…	Part 2: GSK3326595 400mg (…	Part 2: GSK3326595 400mg (…	Part 2: GSK3326595 400mg (…	Part 2: GSK3326595 400mg (…	Part 2: GSK3326595 400mg (…	Part 2: GSK3326595 400mg (…	Part 2: GSK3326595 300mg (…	Part 2: GSK3326595 400mg (…	Part 2: GSK3326595 300mg (…	Part 2: GSK3326595 400mg (…	Part 2: GSK3326595 300mg (…	Part 2: GSK3326595 400mg (…	Part 2: GSK3326595 300mg (…	Part 3: GSK3326595 100mg +…
Anaemia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Dyspnoea	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Acute kidney injury	Renal and urinary disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Pneumonia	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Dehydration	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Pleural effusion	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Pneumothorax	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Hypoxia	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Pain	General disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Brain oedema	Nervous system disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Intracranial pressure increased	Nervous system disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Thrombocytopenia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Respiratory failure	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Escherichia infection	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Pyelonephritis acute	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Sepsis	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Skin infection	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Staphylococcal infection	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Urinary tract infection	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Pyrexia	General disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Fatigue	General disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
General physical health deterioration	General disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Oedema peripheral	General disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Atrial fibrillation	Cardiac disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

Other adverse events (86 terms — click to expand)

Reaction	System	Part 1: GSK3326595 12.5 Mi…	Part 1: GSK3326595 25mg QD	Part 1: GSK3326595 50mg QD	Part 1: GSK3326595 100mg QD	Part 1: GSK3326595 200mg QD	Part 1: GSK3326595 300mg QD	Part 1: GSK3326595 400mg QD	Part 1: GSK3326595 600mg QD	Part 1: GSK3326595 50mg Tw…	Part 1: GSK3326595 100mg BID	Part 1: GSK3326595 150mg BID	Part 1: GSK3326595 200mg BID	Part 1: GSK3326595 300mg Q…	Part 2: GSK3326595 400mg (…	Part 2: GSK3326595 400mg (…	Part 2: GSK3326595 400mg (…	Part 2: GSK3326595 400mg (…	Part 2: GSK3326595 400mg (…	Part 2: GSK3326595 400mg (…	Part 2: GSK3326595 300mg (…	Part 2: GSK3326595 400mg (…	Part 2: GSK3326595 300mg (…	Part 2: GSK3326595 400mg (…	Part 2: GSK3326595 300mg (…	Part 2: GSK3326595 400mg (…	Part 2: GSK3326595 300mg (…	Part 3: GSK3326595 100mg +…
Nausea	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Fatigue	General disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Alopecia	Skin and subcutaneous tissue disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Anaemia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Dysgeusia	Nervous system disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Decreased appetite	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Stomatitis	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Asthenia	General disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Headache	Nervous system disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Dyspnoea	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Dry skin	Skin and subcutaneous tissue disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Oedema peripheral	General disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Constipation	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Weight decreased	Investigations	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Thrombocytopenia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Pruritus	Skin and subcutaneous tissue disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Platelet count decreased	Investigations	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Abdominal pain	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Arthralgia	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Myalgia	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Pyrexia	General disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Dizziness	Nervous system disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Pain in extremity	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Blood bilirubin increased	Investigations	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Vision blurred	Eye disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Dry mouth	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Rash	Skin and subcutaneous tissue disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Neutrophil count decreased	Investigations	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Pneumonia	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Urinary tract infection	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Neutropenia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Hypokalaemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Dyspepsia	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Gastrooesophageal reflux disease	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Peripheral sensory neuropathy	Nervous system disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Rash maculo-papular	Skin and subcutaneous tissue disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

Most-reported serious reactions: Anaemia, Dyspnoea, Acute kidney injury, Pneumonia, Dehydration, Pleural effusion, Pneumothorax, Hypoxia.

Data from ClinicalTrials.gov NCT02783300 adverse events section.

Sponsor's own description

This first time in human (FTIH) open-label, dose escalation study will assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of GSK3326595 in participants with advanced or recurrent solid tumors, as well as clinical activity in participants with a subset of solid tumors and non-Hodgkin's lymphoma (NHL).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Integrative Molecular Characterization of Malignant Pleural Mesothelioma.
Hmeljak J, Sanchez-Vega F, Hoadley KA, Shih J, et al · · 2018 · cited 495× · PMID 30322867 · DOI 10.1158/2159-8290.cd-18-0804
Pancreatic cancer organoids recapitulate disease and allow personalized drug screening.
Driehuis E, van Hoeck A, Moore K, Kolders S, et al · · 2019 · cited 358× · PMID 31818951 · DOI 10.1073/pnas.1911273116
Human organoids in basic research and clinical applications.
Tang XY, Wu S, Wang D, Chu C, et al · · 2022 · cited 298× · PMID 35610212 · DOI 10.1038/s41392-022-01024-9
WD40 repeat domain proteins: a novel target class?
Schapira M, Tyers M, Torrent M, Arrowsmith CH. · · 2017 · cited 256× · PMID 29026209 · DOI 10.1038/nrd.2017.179
Epigenetics and Cancer Stem Cells: Unleashing, Hijacking, and Restricting Cellular Plasticity.
Wainwright EN, Scaffidi P. · · 2017 · cited 250× · PMID 28718414 · DOI 10.1016/j.trecan.2017.04.004
Protein arginine methyltransferases: promising targets for cancer therapy.
Hwang JW, Cho Y, Bae GU, Kim SN, et al · · 2021 · cited 205× · PMID 34006904 · DOI 10.1038/s12276-021-00613-y
Targeting Epigenetics in Cancer.
Bennett RL, Licht JD. · · 2018 · cited 184× · PMID 28992434 · DOI 10.1146/annurev-pharmtox-010716-105106
PRMT5 control of cGAS/STING and NLRC5 pathways defines melanoma response to antitumor immunity.
Kim H, Kim H, Feng Y, Li Y, et al · · 2020 · cited 181× · PMID 32641491 · DOI 10.1126/scitranslmed.aaz5683

Verify or expand the search:

Other trials of GSK3326595

Trials testing the same drug.

NCT04676516 — A Phase II Window of Opportunity Trial of PRMT5 Inhibitor, GSK3326595, in Early Stage Breast Cancer · Phase 2 · completed
NCT03614728 — Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome ( · Phase 1, PHASE2 · terminated

Other recruiting trials for Neoplasms

Currently open trials in the same condition.

NCT07438782 — First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combinatio · Phase 1 · recruiting
NCT07382817 — Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms · Phase 1 · recruiting
NCT07277270 — A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tum · Phase 1 · recruiting
NCT07257640 — IL-5 CAR-T Cell Therapy for Refractory/Relapsed Eosinophilic Leukemia · Phase 1 · recruiting
NCT07213609 — A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer · Phase 1, PHASE2 · recruiting

Other GlaxoSmithKline trials

Trials by the same sponsor.

NCT07569081 — A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflam · Phase 2, PHASE3 · not yet recruiting
NCT07406347 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose · Phase 1 · not yet recruiting
NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting
NCT07286331 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-E · Phase 3 · not yet recruiting
NCT07406334 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02783300 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by GlaxoSmithKline
Last refreshed: 10 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02783300.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT02783300: Meteor 1

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Adverse events — posted to ClinicalTrials.gov

Serious adverse events (114 terms)

Sponsor's own description

Publications & conference data

Related trials

Other trials of GSK3326595

Other recruiting trials for Neoplasms

Other GlaxoSmithKline trials

Verify against primary sources